This activity was originally broadcast in conjunction with AMCP 2024.
Program Description
A chronic, inflammatory disease of the hair follicles, hidradenitis suppurativa (HS) presents with painful nodules and lesions typically near sweat glands. Since HS is not curable, treatment plans include lifestyle changes, topical agents, antibiotics, wound care, and pain management. Emerging therapies target the IL-17 and Janus kinase pathways that are activated in HS. People living with HS may experience years of undertreatment or incorrect treatment, as well as complications that may impact physical, psychological, socioeconomic, and quality-of-life factors. Complexities from both the disease and underlying comorbidities also lead to higher health care utilization costs. Managed care pharmacists need to be aware of the challenges associated with HS so they can allocate health care resources accordingly, reduce treatment disparities, help patients gain appropriate access to new therapies, and alleviate the cost-associated burden. This activity includes an overview of the clinical presentation of HS, severity scoring systems, emerging treatment options, and information on costs and health care utilization rates.
Target audience: Managed care pharmacists
Type of activity: Application
Release date: May 3, 2024
Expiration date: July 24, 2025
Time to complete activity: 1.5 hours
Learner level: Foundational, Intermediate
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Identify the challenges in treatment, the burden of disease, and the severity scoring systems that guide the treatment approach for hidradenitis suppurativa (HS)
- Examine recent clinical safety and efficacy data for current and investigational agents for moderate to severe HS
- Investigate managed care strategies to facilitate appropriate access to new treatments for patients with HS
Amy M. Lugo, PharmD, BCPS, BC-ADM, FAPhA
Founder and CEO
LoneStar Health Solutions
San Antonio, Texas
Jamie L. McConaha, PharmD, NCTTP, BCACP, CDCES
Associate Professor of Pharmacy Practice
Duquesne University School of Pharmacy
Pittsburgh, Pennsylvania
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-9999-24-126-H01-P. The activity is available for CE credit through July 24, 2025.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
The following contributors have no relevant financial relationships with commercial interests to disclose:
Faculty
Amy M. Lugo, PharmD, BCPS, BC-ADM, FAPhA
Jamie L. McConaha, PharmD, NCTTP, BCACP, CDCES
Pharmacy Times Continuing Education™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Adam C. Welch, PharmD, MBA, FAPhA; Kylie Ferrentino; Susan Pordon; Brianna Winters; Chloe Taccetta; and Rebecca Green have no relevant financial relationships with commercial interests to disclose.
Anonymous peer reviewers were used as part of content validation and conflict resolution. The peer reviewers have no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms